seelos therapeutics, inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing of novel technologies and therapeutics for the treatment of central nervous system, respiratory, and other disorders. the company's lead programs are sls-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorder and post-traumatic stress disorder; sls-005, a protein stabilizer for the treatment of sanfilippo syndrome; and sls-006, a partial dopamine agonist for the treatment of patients with parkinson's disease (pd). its preclinical programs include sls-007, an anti-alpha-synuclein peptidic inhibitor to treat patients with pd; sls-008, an orally available antagonist for chemoattractant receptor-homologous molecule for the treatment of chronic inflammation in asthma and pediatric orphan indications; sls-004 for the treatment of pd; sls-010, an oral histamine h3a receptor antagonist for narcolepsy a
Company profile
Ticker
SEEL
Exchange
Website
CEO
Raj Mehra
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
APRICUS BIOSCIENCES, INC., NEXMED INC
SEC CIK
Corporate docs
Subsidiaries
NexMed (U.S.A.), Inc. • Apricus Pharmaceuticals USA, Inc. • NexMed Holdings, Inc. • NexMed International Limited • Seelos Corporation • Seelos Therapeutics Australia Pty Ltd ...
IRS number
870449967
SEEL stock data
Latest filings (excl ownership)
8-K
Entry into a Material Definitive Agreement
3 May 24
10-K/A
2023 FY
Annual report (amended)
29 Apr 24
8-K
Entry into a Material Definitive Agreement
28 Mar 24
8-K
Other Events
19 Mar 24
EFFECT
Notice of effectiveness
18 Mar 24
424B3
Prospectus supplement
15 Mar 24
S-8
Registration of securities for employees
6 Mar 24
S-1/A
IPO registration (amended)
6 Mar 24
10-K
2023 FY
Annual report
6 Mar 24
D
Exempt offering of security
14 Feb 24
Latest ownership filings
4
Michael Joseph Golembiewski
1 Mar 24
SC 13G
Lind Global Fund II LP
6 Feb 24
4
Raj Mehra
17 Jan 24
4
Michael Joseph Golembiewski
17 Jan 24
4
Richard W Pascoe
8 Jan 24
4
MARGARET DALESANDRO
8 Jan 24
4
Brian Lian
8 Jan 24
4
Daniel J. O'Connor
8 Jan 24
4
Michael Joseph Golembiewski
1 Dec 23
4
Raj Mehra
1 Dec 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 2.58 mm | 2.58 mm | 2.58 mm | 2.58 mm | 2.58 mm | 2.58 mm |
Cash burn (monthly) | 1.09 mm | 2.33 mm | 4.20 mm | 4.23 mm | 1.92 mm | 2.92 mm |
Cash used (since last report) | 7.89 mm | 16.90 mm | 30.51 mm | 30.71 mm | 13.92 mm | 21.24 mm |
Cash remaining | -5.31 mm | -14.32 mm | -27.93 mm | -28.13 mm | -11.33 mm | -18.65 mm |
Runway (months of cash) | -4.9 | -6.2 | -6.6 | -6.7 | -5.9 | -6.4 |
Institutional ownership, Q4 2023
15.3% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 6 |
Opened positions | 0 |
Closed positions | 78 |
Increased positions | 0 |
Reduced positions | 5 |
13F shares | Current |
---|---|
Total value | 433.49 mm |
Total shares | 2.53 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
LGND Ligand Pharmaceuticals, Inc. - Ordinary Shares | 2.22 mm | $3.51 mm |
Mirae Asset Global Investments | 303.71 k | $422.16 mm |
Carmichael Hill & Associates | 5.00 k | $6.95 mm |
International Assets Investment Management | 1.14 k | $821.00 k |
FNY Investment Advisers | 66.00 | $0.00 |
Westside Investment Management | 33.00 | $45.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
29 Feb 24 | Michael Joseph Golembiewski | Common Stock | Grant | Acquire A | No | No | 1.097 | 417 | 457.45 | 86,869 |
12 Jan 24 | Mehra Raj | Stock Option Common Stock | Grant | Acquire A | No | No | 1.41 | 70,383 | 99.24 k | 70,383 |
12 Jan 24 | Michael Joseph Golembiewski | Stock Option Common Stock | Grant | Acquire A | No | No | 1.41 | 24,537 | 34.60 k | 24,537 |
4 Jan 24 | O'Connor Daniel J. | Stock Option Common Stock | Grant | Acquire A | No | No | 1.33 | 1,666 | 2.22 k | 1,666 |
4 Jan 24 | Pascoe Richard W | Stock Option Common Stock | Grant | Acquire A | No | No | 1.33 | 1,666 | 2.22 k | 1,666 |
News
"FDA Expert Committee Will Review MDMA-Assisted Therapy For PTSD Next Month" - Marijuana Moment
7 May 24
12 Health Care Stocks Moving In Monday's After-Market Session
29 Apr 24
Seelos Therapeutics Announces Strategic Focus On Mental Health Initiatives And Provides An Update On Current Discussions Of Potential Partnerships And Collaboration; Richard Pascoe Appointed Chairman Of The Board
29 Apr 24
Why Lifecore Biomedical Shares Are Trading Lower By Around 32%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
20 Mar 24
12 Health Care Stocks Moving In Wednesday's Intraday Session
20 Mar 24